Updates and Events
Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.  Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] READ MORE

More Women with Lupus Having Families

July 12, 2019 In years past, doctors had advised most women with lupus to avoid getting pregnant because of the high risk for both mother and fetus.  A newly published study in Annals of Internal Medicine by Dr. Bella Mehta shows that more women with lupus are having successful pregnancies, while the accompanying editorial by […] READ MORE

LRA-Funded Researchers Present Cutting-Edge Science at FOCIS

July 11, 2019 The annual meeting of the Federation of Clinical Immunology Societies (FOCIS) is the key forum for translational immunology. The Lupus Research Alliance (LRA) is proud to co-sponsor this meeting, which allows researchers and clinicians to share knowledge across disease borders and to chart the path to the next major breakthroughs in disease […] READ MORE

Top Research Needs to Help Kids with Lupus

July 5, 2019 A study published last week in Pediatric Rheumatology identified the top priorities for research into lupus in children. The survey asked pediatric rheumatologists, dermatologists and nephrologists with expertise in lupus to categorize areas of research into high, medium or low priority.  The survey was given to pediatric rheumatologists, dermatologists and nephrologists with […] READ MORE

National Stay Out of the Sun Day

July 3, 2019 Avoiding the sun is something most people with lupus know they just have to live with.  About half of people with lupus experience a “malar” rash that may appear across the cheeks and bridge of the nose in the shape of a butterfly.  Many are sensitive to sunlight (called photosensitivity) meaning that […] READ MORE

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] READ MORE

Skin Molecules Promote Cutaneous Lupus

June 24, 2019 Patients with cutaneous lupus develop rashes because immune cells move into the skin and cause inflammation. With a Target Identification in Lupus (TIL) grant from the Lupus Research Alliance, Dr. Jillian Richmond of the University of Massachusetts Medical School and colleagues found what lures the immune cells into the skin of people […] READ MORE

Possible Cancer Drug 2DG May Boost Good Immune Cells

June 20, 2019 The investigational drug 2DG, tested as a cancer treatment, shows promise for lupus in new results reported by researchers from Japan at the European League Against Rheumatism (EULAR) 2019 annual meeting. Previous research had shown that the a potential drug, 2DG, increases the numbers of regulatory T cells, which turn down the […] READ MORE

NIH Work Co-Supported by LRA May Simplify Lupus Nephritis Monitoring

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […] READ MORE

$10 Million for Lupus Research Program Passed by House: Your Advocacy Works!

NEW YORK, NY. June 19, 2019. The U.S. House of Representatives today passed the Fiscal Year 2020 Defense Appropriations Act, which allocates the Lupus Research Alliance advocate’s full request for $10 million — double the current budget — for the Lupus Research Program in the Department of Defense’s (DoD) Congressionally Directed Medical Research Program. The […] READ MORE

LRA-Supported Discovery Highlighted at EULAR

June 19,2019 Partly funded by the Lupus Research Alliance, new results presented at the European Congress of Rheumatology (EULAR) 2019 suggest that some potential cancer treatments may also help patients with lupus.  Dr. Amr Sawalha of the University of Pittsburgh and colleagues have discovered a similarity between immune cells in lupus and some kinds of […] READ MORE

Learn and connect with our community!